Chronic Kidney Disease Clinical Trial
Official title:
A Single Centre Observational Cohort Study on the Prognostic Relevance of P-cresol and Related Uremic Retention Solutes in the Development and/or Progression of Renal Failure and Cardiovascular Disease in Chronic Kidney Disease Patients
Study on the natural history of uremic retention solutes in patients with mild-to-moderate chronic kidney disease
Protein-bound uremic retention solutes are increasingly recognized to play a role in the
pathophysiology of the uremic syndrome. Numerous in vitro findings are indicative for their
implication in the biochemical and physiological changes of uremia. Several of these
protein-bound retention solutes originate from bacterial protein fermentation in the colon.
p-cresyl sulfate, a fermentation metabolite of the amino acid tyrosine, is considered a
prototype of this group of uremic solutes. The protein binding of this molecule was shown to
be about 90% in end-stage renal disease patients. Several data have suggested that p-cresol
plays a role in the immunodeficiency of uremia. Recently, a link between the molecule and
endothelial dysfunction has been demonstrated. Also other members of the class of
protein-bound solutes have been found to be associated with immune dysfunction, endothelial
cell dysfunction and, closely related to the latter, oxidative stress.
Free serum levels of p-cresol were shown to be greater in stage 5 chronic kidney disease
(CKD) patients treated with hemodialysis (HD) hospitalized for infectious disease.
Furthermore, a positive relationship was found between serum total p-cresol level and a
uremic symptom score in patients treated with peritoneal dialysis (PD), whereas a
correlation with small water-soluble solutes and the middle molecule β2-microglobulin was
absent. A recent prospective observational study in stage 5 CKD patients treated with
conventional HD (3 x 4 hours per week) indicated that the accumulation of p-cresol is a risk
factor for overall mortality.
Data on the serum concentrations of p-cresol in chronic kidney disease patients are lacking.
The investigators hypothesise that the serum concentration of p-cresol is an independent
predictor of progression to end stage renal disease and is an independent predictor for
cardiovascular disease.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
| Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
| Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
| Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
| Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
| Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
| Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
| Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
| Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
| Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
| Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
| Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
| Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
| Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
| Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
| Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
| Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
| Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
| Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |